These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 30509215)
1. Short-term dexamethasone treatment transiently, but not permanently, attenuates fibrosis after acute-to-chronic kidney injury. Moonen L; Geryl H; D'Haese PC; Vervaet BA BMC Nephrol; 2018 Dec; 19(1):343. PubMed ID: 30509215 [TBL] [Abstract][Full Text] [Related]
2. Unilateral Renal Ischemia-Reperfusion as a Robust Model for Acute to Chronic Kidney Injury in Mice. Le Clef N; Verhulst A; D'Haese PC; Vervaet BA PLoS One; 2016; 11(3):e0152153. PubMed ID: 27007127 [TBL] [Abstract][Full Text] [Related]
3. CSF-1R inhibition attenuates ischemia-induced renal injury and fibrosis by reducing Ly6C Deng X; Yang Q; Wang Y; Zhou C; Guo Y; Hu Z; Liao W; Xu G; Zeng R Int Immunopharmacol; 2020 Nov; 88():106854. PubMed ID: 32771945 [TBL] [Abstract][Full Text] [Related]
4. A short treatment with resveratrol after a renal ischaemia-reperfusion injury prevents maladaptive repair and long-term chronic kidney disease in rats. Martínez-Rojas MÁ; Balcázar H; Ponce-Nava MS; González-Soria I; Marquina-Castillo B; Pérez-Villalva R; Bobadilla NA J Physiol; 2024 Apr; 602(8):1835-1852. PubMed ID: 38529522 [TBL] [Abstract][Full Text] [Related]
7. The role of podocyte damage in the etiology of ischemia-reperfusion acute kidney injury and post-injury fibrosis. Chen Y; Lin L; Tao X; Song Y; Cui J; Wan J BMC Nephrol; 2019 Mar; 20(1):106. PubMed ID: 30922260 [TBL] [Abstract][Full Text] [Related]
8. Dexmedetomidine attenuates renal fibrosis via α2-adrenergic receptor-dependent inhibition of cellular senescence after renal ischemia/reperfusion. Li Q; Chen C; Chen X; Han M; Li J Life Sci; 2018 Aug; 207():1-8. PubMed ID: 29729264 [TBL] [Abstract][Full Text] [Related]
9. Divergent effects of AKI to CKD models on inflammation and fibrosis. Black LM; Lever JM; Traylor AM; Chen B; Yang Z; Esman SK; Jiang Y; Cutter GR; Boddu R; George JF; Agarwal A Am J Physiol Renal Physiol; 2018 Oct; 315(4):F1107-F1118. PubMed ID: 29897282 [TBL] [Abstract][Full Text] [Related]
10. Cellular communication network factor 2 (CCN2) promotes the progression of acute kidney injury to chronic kidney disease. Inoue T; Kusano T; Amano H; Nakamoto H; Okada H Biochem Biophys Res Commun; 2019 Sep; 517(1):96-102. PubMed ID: 31320136 [TBL] [Abstract][Full Text] [Related]
11. Differential role of nicotinamide adenine dinucleotide deficiency in acute and chronic kidney disease. Faivre A; Katsyuba E; Verissimo T; Lindenmeyer M; Rajaram RD; Naesens M; Heckenmeyer C; Mottis A; Feraille E; Cippà P; Cohen C; Longchamp A; Allagnat F; Rutkowski JM; Legouis D; Auwerx J; de Seigneux S Nephrol Dial Transplant; 2021 Jan; 36(1):60-68. PubMed ID: 33099633 [TBL] [Abstract][Full Text] [Related]
12. Delivery of interleukin-10 via injectable hydrogels improves renal outcomes and reduces systemic inflammation following ischemic acute kidney injury in mice. Soranno DE; Rodell CB; Altmann C; Duplantis J; Andres-Hernando A; Burdick JA; Faubel S Am J Physiol Renal Physiol; 2016 Aug; 311(2):F362-72. PubMed ID: 26962109 [TBL] [Abstract][Full Text] [Related]
13. cMet agonistic antibody prevents acute kidney injury to chronic kidney disease transition by suppressing Smurf1 and activating Smad7. Li L; Lee J; Cho A; Kim JH; Ju W; An JN; Park JH; Zhu SM; Lee J; Yu SS; Lim CS; Kim DK; Kim YS; Yang SH; Lee JP Clin Sci (Lond); 2021 Jun; 135(11):1427-1444. PubMed ID: 34061176 [TBL] [Abstract][Full Text] [Related]
14. Blockade of cysteine-rich protein 61 attenuates renal inflammation and fibrosis after ischemic kidney injury. Lai CF; Lin SL; Chiang WC; Chen YM; Wu VC; Young GH; Ko WJ; Kuo ML; Tsai TJ; Wu KD Am J Physiol Renal Physiol; 2014 Sep; 307(5):F581-92. PubMed ID: 24920753 [TBL] [Abstract][Full Text] [Related]
16. Anti-anemia drug FG4592 retards the AKI-to-CKD transition by improving vascular regeneration and antioxidative capability. Wu M; Chen W; Miao M; Jin Q; Zhang S; Bai M; Fan J; Zhang Y; Zhang A; Jia Z; Huang S Clin Sci (Lond); 2021 Jul; 135(14):1707-1726. PubMed ID: 34255035 [TBL] [Abstract][Full Text] [Related]
17. Recombinant α-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy. Hu MC; Shi M; Gillings N; Flores B; Takahashi M; Kuro-O M; Moe OW Kidney Int; 2017 May; 91(5):1104-1114. PubMed ID: 28131398 [TBL] [Abstract][Full Text] [Related]
18. BET inhibitor nanotherapy halts kidney damage and reduces chronic kidney disease progression after ischemia-reperfusion injury. Saiz ML; Lozano-Chamizo L; Florez AB; Marciello M; Diaz-Bulnes P; Corte-Iglesias V; Bernet CR; Rodrigues-Diez RR; Martin-Martin C; Rodriguez-Santamaria M; Fernandez-Vega I; Rodriguez RM; Diaz-Corte C; Suarez-Alvarez B; Filice M; Lopez-Larrea C Biomed Pharmacother; 2024 May; 174():116492. PubMed ID: 38537579 [TBL] [Abstract][Full Text] [Related]
19. Renal ischemia-reperfusion injury causes hypertension and renal perfusion impairment in the CD1 mice which promotes progressive renal fibrosis. Greite R; Thorenz A; Chen R; Jang MS; Rong S; Brownstein MJ; Tewes S; Wang L; Baniassad B; Kirsch T; Bräsen JH; Lichtinghagen R; Meier M; Haller H; Hueper K; Gueler F Am J Physiol Renal Physiol; 2018 May; 314(5):F881-F892. PubMed ID: 29357437 [TBL] [Abstract][Full Text] [Related]
20. Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression. Tampe B; Steinle U; Tampe D; Carstens JL; Korsten P; Zeisberg EM; Müller GA; Kalluri R; Zeisberg M Kidney Int; 2017 Jan; 91(1):157-176. PubMed ID: 27692563 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]